Garth Cumberlidge, president and chief executive of Mimetogen Pharmaceuticals Inc, has been appointed chairman of Eyevensys SAS, a biotech company developing therapeutics for ophthalmic diseases.
Dr Cumberlidge has previously served as CEO and president of Qbiogene Inc, and held senior positions at ICN Pharmaceuticals and Sigma Chemicals Co. He holds PhDs from both University College London, UK and the Max-Planck-Institute for Molecular Genetics in Berlin, Germany.
Eyevensys announced the appointment on 21 March 2017
Copyright 2017 Evernow Publishing Ltd